On February 14, 2025, Otsuka Pharmaceutical Co., Ltd. announced that the FDA has approved Romvimza (Vimseltinib) for the treatment of adults with non-metastatic tenosynovial giant cell tumor (TGCT) that may cause functional deterioration or significant morbidity, following surgical resection. The FDA had previously granted Romvimza Fast Track designation and Priority Review status.
TGCT is a rare, locally invasive benign tumor originating from the synovium of joints, bursae, and tendon sheaths, primarily composed of synovial cells. It typically occurs in the joints of the hands and feet.
Pathogenesis: It was previously hypothesized that the pathogenesis of TGCT might be related to inflammation, trauma, and metabolic abnormalities; however, the prevailing view is that the primary mechanism is a gene mutation of colony-stimulating factor 1 (CSF-1). A translocation mutation on chromosome 1 (1p13) affects the CSF1 gene. In TGCT, CSF1 is overexpressed in a few tumor cells, generating a CSF1 concentration gradient that attracts cells expressing CSF1R (mainly macrophages), leading to abnormal aggregation and forming a mass. Based on the growth pattern, TGCT can be classified into localized (L-TGCT) and diffuse (D-TGCT) types. L-TGCT is more common and frequently occurs in the knee, hand, and wrist joints. D-TGCT is more aggressive and often found in the knee, ankle, and hip joints. Patients typically present with pain, swelling, stiffness, and limited range of motion, and some may have hemorrhagic joint effusion. D-TGCT patients tend to be younger than those with L-TGCT, with a higher prevalence in females. If untreated or with recurrent tumor regrowth, it can lead to damage and degeneration of the affected joint and surrounding tissues, resulting in significant disability.
Epidemiology: The incidence of TGCT varies across regions and populations. Studies abroad show an annual incidence rate of 1.8-50 per million. In China, the male-to-female ratio is 1:1.78, with onset typically between the ages of 20 and 50. Moreover, the standardized incidence rate of diffuse TGCT (D-TGCT) is 4 cases per million, while localized TGCT (L-TGCT) is 10 cases per million. The incidence of TGCT has been increasing annually. As a non-fatal tumor, TGCT has a cumulative effect on patients, with a large population of existing patients. Currently, there are about 300,000 existing patients in China and nearly 100,000 in the United States.
Vimseltinib is a selective small molecule inhibitor that specifically regulates the tyrosine kinase activity of colony-stimulating factor 1 receptor (CSF1R) and platelet-derived growth factor receptor alpha (PDGFRα), both of which are overexpressed in TGCT tumor cells. Vimseltinib is provided in capsule form with specifications of 30 mg/14 mg/20 mg. The recommended dose is 60 mg, taken once daily orally until disease progression or unacceptable toxicity. Dose adjustments may be needed based on individual patient safety and tolerance.
The FDA's approval is based on the efficacy and safety results from the pivotal Phase III MOTION trial (NCT05059262) of Romvimza in TGCT patients. The MOTION study was a two-cohort, randomized, double-blind, placebo-controlled Phase III clinical trial that enrolled 123 patients, with 83 receiving vimseltinib treatment and 40 receiving a placebo. The study aimed to evaluate the efficacy and safety of vimseltinib in TGCT patients who had not received prior CSF1/CSF1R-targeted therapy (previous treatment with imatinib or nilotinib was allowed) and were not suitable for surgery. The primary endpoint was the objective response rate (ORR) assessed by independent radiological review (IRR) using RECIST v1.1 criteria in the intent-to-treat (ITT) population at week 25, compared to placebo. Secondary endpoints included ORR assessed by tumor volume score (TVS), range of motion, physical function, stiffness, quality of life, and pain improvement.
Primary Endpoint
At week 25, the ORR for the vimseltinib group was 40% (95% CI: 29%-51%), compared to 0% for the placebo group (p<0.0001). Complete response (CR) was seen in 4 patients (5%), partial response (PR) in 29 patients (35%), and stable disease (SD) in 42 patients (51%).
Secondary Endpoints
Safety
Most treatment-related adverse events (TEAEs) were grade 1 or 2. Common adverse reactions included periorbital edema (45%), fatigue (33%), facial edema (31%), pruritus (29%), headache (28%), weakness (27%), nausea (25%), elevated creatinine (24%), and increased aspartate aminotransferase (AST) (23%). No severe adverse reactions such as cholestatic liver toxicity or drug-induced liver injury were observed.
The market for TGCT treatment is rapidly evolving. Apart from Romvimza, Turalio (Pexidartinib), developed by Daiichi Sankyo, is the first FDA-approved CSF1R inhibitor for TGCT, which also inhibits KIT and FLT3, and is suitable for patients whose functional impairment or morbidity cannot be improved by surgery. Romvimza has a better tolerance and requires fewer doses (once weekly) compared to Turalio (twice daily), providing an advantage. Additionally, Pimicotinib (ABSK021), developed by HeYu Pharma, has entered Phase Ib trials, showing promising efficacy and safety.
In addition to single or multi-targeted chemical drugs, Emactuzumab, a monoclonal antibody specifically targeting CSF1R, is undergoing a Phase III clinical trial (TANGENT study, NCT05417789) to further assess its efficacy and safety in the treatment of TGCT. This drug has received orphan drug designation from the EMA. As a next-generation CSF-1R inhibitor, it features a rapid onset of action, short treatment cycle, and long-lasting responses, making it a promising first-line treatment for TGCT.
[1]. Garner, M., Turner, M., Ghadially, R., & Krewski, D.Epidemiology and Risk Factors for Testicular Cancer: A Systematic Review.European Urology, 2024.
[2]. Ehrenstein V, Andersen SL, Qazi I, Sankar N, Pedersen AB, Sikorski A, Acquaviva J. Tenosynovial Giant Cell Tumor: Incidence, prevalence, patient characteristics, and recurrence. A registry-based cohort study in Denmark. J Rheumatol. 2017;44(10):1476-1483.
|
